Measuring HIV neutralization in a luciferase reporter gene assay.
about
HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activityEASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitorsTopical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replicationStructural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodiesStructures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designThermodynamic Signatures of the Antigen Binding Site of mAb 447–52D Targeting the Third Variable Region of HIV-1 gp120Lignosulfonic acid exhibits broadly anti-HIV-1 activity--potential as a microbicide candidate for the prevention of HIV-1 sexual transmissionA multi-targeted drug candidate with dual anti-HIV and anti-HSV activityGeneration and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern AfricaHIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimersUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinSoluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea PigsSulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor.Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine.Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigsDifferential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model.V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP TrimersBoosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimerProtection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies.Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.Selective impact of HIV disease progression on the innate immune system in the human female reproductive tract.Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesHuman immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C.Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.Designing a soluble near full-length HIV-1 gp41 trimer.Importance of codon usage for the temporal regulation of viral gene expressionEnhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant.Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers
P2860
Q21076115-0480BCD5-7663-4FAC-8C91-C74230AAC540Q24606095-A7038AAA-3C0F-4619-B8DF-F716B8F357B4Q24634299-76F2ABB9-8ADC-436D-AFCB-A09F8782D287Q27643993-DD80F2AA-A930-40EF-870A-3729EDE48AAEQ27644515-A7A6934E-6E00-4E31-B7BF-53DD98DA0CAFQ27644634-62D31058-4F66-43CA-8C6C-A1700DA4F6E5Q27679559-38424E4B-0DC2-4128-B8FD-665895006600Q28482818-974F30F2-AAC4-45E6-A5AF-A81C7C7C0BC9Q28534866-8CD16E39-77DB-47EF-AA04-6177044727CAQ28552786-42D036FE-22A1-4F60-86B5-5DEE5F9FE8AEQ28647225-A61930EB-0C5C-4B29-BBAE-2137D08B01EFQ28730561-6AF62F79-1684-48C4-AD13-730A3AC62C63Q28732438-00450B70-F2A5-4AF9-B033-7D43E073E17DQ30278897-DD90DE47-073B-455C-AABB-ECEA3AB63398Q30391222-ABB9BB93-690B-4D80-821D-BA24C316A785Q30657338-1DF668D8-AD19-47C2-AC79-31D348921D1EQ32183405-BCD739D2-25F4-4D1F-B8F1-9E0AF6E767B4Q33518005-EF8F8B44-A4F1-4F0D-A91A-E300A1F1B6ACQ33693391-9D689BCE-252C-4134-A96C-A787ED856980Q33725679-EEE9919F-2D0C-4F0B-B9F6-0DF8069DDA20Q33827798-9E5B6324-6AAF-4906-9447-BA3A1C09D309Q33873719-884A49F7-523A-4B72-971D-0DFF04427973Q33874253-E86A5FD3-7F3F-49FA-86B4-3A31D036123AQ33900395-160B6BF5-3136-4977-A989-F2364F532FF2Q33907694-307B32DC-94B0-4405-B299-B96052D598E6Q33955745-F3597476-D152-4B10-AFA6-D040AC1A947EQ34034659-A629F56C-1682-4FB0-8610-9B757DFE2472Q34059543-54328624-790A-46A4-96E3-52CD5B189127Q34117097-59E1FAB2-B52F-49B8-89E9-A0FC0E16582EQ34292622-FE3E1969-B5AC-484C-AE63-31ED2C7C2320Q34295695-2636B1FB-2071-41B3-8822-E40E45B7D11CQ34357068-2831DD93-CB89-4875-A51F-9C95D2281960Q34392963-5BA0FAC3-DE7B-4DDF-8A47-36E7833DE286Q34407843-350BF5AA-85AD-42D0-ABBC-A7CE6BC45E96Q34478387-E49223AB-57FC-4A3D-A5B0-DA0CC77D7B9AQ34488183-154CB44C-2963-4167-BA8D-40DBDFC9FD7FQ34489464-27144EA3-E9EE-473F-A25D-42868A8E2B1AQ34499526-037A72A1-5F93-4B1E-ACBF-652E0F0AEDCDQ34576055-1D2F61FA-FBB6-4256-9642-0F1EEE63F12FQ34589611-35B20386-77BE-4E23-A345-67F151D1034F
P2860
Measuring HIV neutralization in a luciferase reporter gene assay.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Measuring HIV neutralization in a luciferase reporter gene assay.
@en
Measuring HIV neutralization in a luciferase reporter gene assay.
@nl
type
label
Measuring HIV neutralization in a luciferase reporter gene assay.
@en
Measuring HIV neutralization in a luciferase reporter gene assay.
@nl
prefLabel
Measuring HIV neutralization in a luciferase reporter gene assay.
@en
Measuring HIV neutralization in a luciferase reporter gene assay.
@nl
P1476
Measuring HIV neutralization in a luciferase reporter gene assay.
@en
P304
P356
10.1007/978-1-59745-170-3_26
P407
P577
2009-01-01T00:00:00Z